Virus therapy targets Hard-to-Treat tumors in early trial
NCT ID NCT07584668
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This early-stage study tests the safety of a new virus-based drug called EM-I-2024 in 24 adults with advanced solid tumors that cannot be removed by surgery and have not responded to other treatments. The drug is given either through a vein or directly into the artery feeding the tumor, depending on how far the cancer has spread. The main goal is to see if the drug is safe and how it behaves in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASSESS THE SAFETY AND TOLERABILITY OF VARIOUS DOSES AND DOSING SCHEDULES OF ENTEROMIX IN PATIENTS WITH A HISTOLOGICALLY CONFIRMED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
FSBI National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation
Moscow, 117630, Russia
Conditions
Explore the condition pages connected to this study.